|Martin Kampmann, PhD|
|Michael Keiser, PhD|
Yesterday, the Chan Zuckerberg Initiative (CZI) launched the CZI Neurodegeneration Challenge Network. This new network brings together scientists from diverse research fields to understand the underlying causes of neurodegenerative diseases. Following an international open call for applications, two IND faculty, Martin Kampmann and Michael Keiser, were among the 17 recipients of a Ben Barres Early Career Acceleration Award, which provides $2.5 million in research funding for each recipient. The Award is named for the late Ben Barres, eminent neurobiologist who was also openly transgender and a fierce advocate for young scientists, women, mentorship, and diversity in science. The Kampmann lab has developed CRISPR-based functional genomics approaches in neurons and glia derived from human induced pluripotent stem cells to uncover mechanisms and therapeutic targets for neurodegenerative diseases. The Keiser lab has developed computational approaches, using tools such as human-interpretable deep learning, to decode the biological mechanisms of promising new drugs and drug-like molecules for these devastating diseases.